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Abstract
Background: The direct oral anticoagulants (DOACs), apixaban and rivaroxaban, have
been studied for extended-phase treatment of venous thromboembolism (VTE). Yet,
scant evidence exists surrounding clinician practice and decision-making regarding
dose reduction.
Aims: Report clinician practice and characteristics surrounding dose reduction of
DOACs for extended-phase VTE treatment.
Methods: We conducted a 16-question REDCap survey between July 14, 2021, and
September 13, 2021, among ISTH 2021 Congress attendees and on Twitter. We
explored factors associated with dose reduction using logistic regression. We used
k-means clustering to identify distinct groups of dose-reduction decision-making.
Random forest analysis explored demographics with respect to identified groups.
Results: Among 171 respondents, most were attending academic physicians from
North America. Clinicians who treated larger volumes of patients had higher odds of
dose reduction. We identified five clusters that showed distinct patterns of behavior
regarding dose reduction. Cluster 1 rarely dose reduces and likely prescribes rivaroxaban over apixaban; cluster 2 dose reduces frequently, does not consider age when
dose-reducing, is least likely to temporarily reescalate dosing, and prescribes apixaban and rivaroxaban equally; cluster 3 dose reduces <50% of the time, and temporarily reescalates dosing during increased VTE risk; cluster 4 dose reduces frequently,
temporarily reescalates dosing, and is most likely to prescribe apixaban over rivaroxaban; and cluster 5 dose reduces most frequently, and takes the fewest risk factors into
consideration when deciding to dose reduce.
Conclusions: Most clinicians elect to dose-reduce DOACs for extended-phase anticoagulation. The likelihood of a clinician to dose reduce increases with volume of
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patients treated. Clinician prescribing patterns cluster around VTE risk factors as well
as reescalation during high-risk periods.
KEYWORDS

anticoagulant, apixaban, reduced-dose, rivaroxaban, treatment, venous thromboembolism

Essentials
• Extended phase direct oral anticoagulants (DOACs) are used to prevent 2° venous thrombosis (VTE).
• Clinicians variably elect reduced-dose DOACs apixaban & rivaroxaban to prevent 2° VTE.
• We surveyed 171 ISTH2021 & Twitter™ respondents about DOAC prescription to prevent 2° VTE.
• Most respondents were academic & elect dose-reduction-especially if they treat many patients.
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I NTRO D U C TI O N

Thrombosis Research Society and sponsored by the Anticoagulation
Forum, National Blood Clot Alliance, and American Society of

Patients who experience deep vein thrombosis (DVT) and pulmo-

Hematology Foundation. Survey questions were generated during

nary embolism (PE) in the absence of an identifiable, transient, major

standing VENUS committee meetings and then iteratively refined

provoking factor1 are often advised to continue anticoagulation

by the members of the subcommittee via email consensus. The final

indefinitely. 2-4 Extended-phase therapy with anticoagulation is con-

survey (Appendix S1) included clinician demographic and practice

tinued for the prevention of recurrent thrombosis after the treat-

characteristics, as well as clinical situations that were hypothe-

ment phase (usually 3–6 months) is completed. Various direct oral

sized based on VTE literature to potentially impact dose-reduction

anticoagulants (DOACs) have been studied for the prevention of re-

behaviors.

current thrombosis.5-7 Two DOACs, apixaban and rivaroxaban, have

A targeted population-specific survey design was selected. A

evidence reporting the effectiveness and safety of reduced dose

REDCap link was linked to the survey questionnaire. The survey was

compared with treatment phase dose anticoagulation for extended-

first deployed as part of the International Society of Thrombosis

phase therapy.5,7 Meta-analysis of these studies demonstrated

and Haemostasis (ISTH) 2021 meeting.19 The ISTH includes more

that over 1 year, reduced-dose DOAC therapy was as effective as

than 5000 clinicians and researchers in more than 100 countries. A

treatment-phase dose therapy to prevent recurrent venous throm-

link to the survey was embedded in the ISTH2021 Congress daily

bosis (VTE; relative risk 0.85; 95% confidence interval [CI] 0.51–

email newsletter, and posted during the meeting by investigators on

1.42) and had a trend toward less bleeding (relative risk 0.74; 95%

the ISTH2021 Twitter feed. Second, an explanatory paragraph ac-

CI 0.52–1.05).8 Subsequently, the US Food and Drug Administration

companied by an embedded link to the survey was disseminated by

approved the reduced-dose regimens of apixaban and rivaroxaban

email to members of VENUS and the Hemostasis and Thrombosis

for reducing the risk of recurrent DVT and PE following the treat-

Research Society, 20 a North American professional society dedi-

ment phase of 6–12 months.9,10 However, concern exists surround-

cated to research, education, investigation, and advancement of

ing the dose reduction of DOACs among certain patient populations

work in hemostatic and thrombotic disorders. Last, VENUS mem-

thought to be at a higher than usual risk for recurrent thrombosis.

bers on Twitter created Twitter posts with a pithy explanation of the

These include patients with obesity,11,12 cancer,13,14 and antiphos-

study and an embedded link to the REDCap survey. The survey was

pholipid syndrome.15,16 Yet, little is known regarding physician pref-

initiated on July 14, 2021, and closed on September 13, 2021. Study

erences in selecting anticoagulants17 and how physicians elect to

review was performed, and a waiver of signed informed consent was

either continue treatment- or reduced-dose anticoagulation for the

granted by the Intermountain Healthcare institutional review board.

prevention of recurrent VTE. Therefore, we conducted a study to

No financial support existed for the study.

better understand physician decision-making regarding DOAC dose
reduction for extended-phase anticoagulation treatment.

Survey responses were described with descriptive statistics.
Logistic regression was performed to assess demographics associated with electing dose reduction. In a sensitivity analysis, probit
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M E TH O D S

regression was used to identify demographics associated with frequency of dose reduction (rarely, sometimes, usually).
To understand whether identifiable cohorts of respondents ap-

This work was conducted by members the Venous ThromboEmbolism

proached dose reduction in a similar fashion, we used an unsuper-

Network U.S. (VENUS)18 Subcommittee on Venous thromboem-

vised machine learning approach using clustering. We searched for

bolism Treatment and Anticoagulation Management. VENUS is a

the optimal number of clusters (2 ≤ k ≤ 10) with k-means cluster-

collaborative working group administered by the Hemostasis and

ing by minimizing the silhouette score while maintaining sufficient

|
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cluster size (n ≥ 20). 21 Leveraging simulations by Dalmaiher et al., 22

travel. When asked whether they preferentially prescribe one DOAC

we anticipate almost 100% accuracy for detecting the correct num-

over another, 46.8% of respondents preferentially prescribed apix-

ber of clusters when recruiting 200 participants. A visual inspection

aban, compared with 15.2% who preferentially prescribed rivarox-

of the first two components of a principal component analysis was

aban. Eighty-t wo percent of respondents stated they dose reduce

used to ensure sufficient distinctness between identified clusters.

with each medication equally. Additional dosing behaviors are found

Dosing behaviors of the clusters were described with descriptive

in Table 2.

statistics, and frequencies were depicted with a heatmap.

Compared with respondents who treated fewer than 50 patients

We used a random forest approach to identify the importance

annually, respondents who treated greater than 250 patients annu-

of respondent demographics with respect to model accuracy in pre-

ally had a 6.8-fold (odds ratio [OR] 6.8; 95% CI 1.36–37.75; p = 0.02)

23

Hyperparameters were

greater odds and those who treated 151–250 patients annually had

optimized with a grid search and model performance was assessed

a 4.0-fold (OR 4.0; 95% CI 1.01–16.33; p = 0.05) greater odds of

dicting DOAC dosing-behavior groups.

with out-of-bag estimate of error. A randomly selected subset of
samples are used to train the decision trees. After the decision trees

TA B L E 1 Demographics of survey participants

are trained on selected samples, the samples left out, or out-of-bag,

Attribute

are then presented to the decision trees for prediction. The out-of-

Status

bag-error rate is then computed as the number of errors that were
predicted from the out-of-bag sample. All analyses were conducted
using R version 4.0.3.

3
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R E S U LT S

Among the 172 individuals that accessed the survey, 171 engaged
in the survey and 170 responded to all questions. Most (86.5%) respondents self-identified as attending physicians, 84.2% reported
practicing in an academic setting, 67.8% were from North America,
50.3% had been practicing for fewer than 10 years, 38% spent

Attending physician

N (%)

148 (86.5%)

Nurse practitioner/physician assistant/mid-level
provider

10 (5.8%)

Trainee (student, resident, fellow)

13 (7.6%)

Specialty
Thrombosis

75 (43.9%)

Other

96 (56.1%)

Setting
Academic
Nonacademic

144 (84.2%)
27 (15.8%)

Percent of clinical time is outpatient care

greater than 80% of their clinical time in an ambulatory setting, and

<50

34 (19.9%)

24.6% prescribed more than 250 DOAC prescriptions annually. See

50–79

71 (41.5%)

≥80

65 (38.0%)

Table 1 for additional demographics.
Among all respondents, 82.5% reported that they dose-reduce
DOACs. Among those who dose reduce, 38% do so rarely (<25%
of the time), 31.6% do so sometimes (25%–49% of the time), and
46.2% do so between 50% and 100% of the time. When asked to
consider specific patient populations in which they refrain from
dose reduction, 76.6% of participants responded that they refrain
from dose reduction in patients with cancer, 66.7% in patients with
antiphospholipid syndrome (for which vitamin K antagonists are
15

recommended ), 66.1% in patients who had prior VTE while receiving anticoagulation therapy, 64.9% in patients with recurrent VTE,

Years in practice
≤10

86 (50.3%)

11–25

69 (40.4%)

>25

16 (9.4%)

Number of patients where you are involved in DOAC prescriptions
<50

16 (9.4%)

51–250

51 (29.8%)

>250

42 (24.6%)

Institutional protocol to consider DOAC dose adjustment in place

and 53.8% in patients that are obese. When asked to consider the

Yes

14 (8.2%)

likelihood of dose reduction in certain clinical situations, 84.8% of

No

93 (54.4%)

respondents stated that they would preferentially elect dose reduc-

Don't know

61 (35.7%)

tion in patients with a history of bleeding, 77.2% in patients with
a history of distal DVT, 74.9% in patients prescribed concomitant
platelet therapy, and 44% in patients with unusual site thrombosis.
Sixty-t wo percent of respondents reported that they engage in temporary reescalation of DOAC dosing. When asked to consider clinical
scenarios in which they elect to temporarily escalate DOAC dosing,
79% stated that they would do so in the setting of a new diagnosis of
cancer, 75.8% in patients in the postoperative setting, 48.4% in patients requiring hospitalization, 45.3% in patients who have become
bedbound or immobilized, and 21% in patients engaged in long-haul

Country
North America

116 (67.8%)

Europe

31 (18.1%)

Other

24 (14.0%)

US region, n = 98
East

43 (43.9%)

Midwest

34 (34.7%)

West

21 (21.4%)

Abbreviation: DOAC, direct oral coagulant.
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TA B L E 2 Dosing behaviors of survey participants
Attribute

N (%)

TA B L E 2 (Continued)
Attribute

N (%)

DOAC prescribed

Reduce dosage
Yes

141 (82.5%)

No

30 (17.5%)

Frequency

Apixaban

80 (46.8%)

Prescribe apixaban and rivaroxaban equally

65 (38%)

Rivaroxaban

26 (15.2%)

Medication reduced

Usually (50%–100%)

79 (46.2%)

Sometimes (25%–49% of the time)

54 (31.6%)

Both

Rarely (0%–24%)

38 (22.2%)

Apixaban

12 (7%)

Neither

12 (7%)

Risk factors to NOT dose reduce
Cancer

131 (76.6%)

Rivaroxaban

Antiphospholipid syndrome (if applicable to
your practice)

114 (66.7%)

More comfortable

Prior VTE event on therapy

113 (66.1%)

Recurrent VTE

111 (64.9%)

140 (81.9%)

7 (4.1%)

No

150 (87.7%)

Yes

21 (12.3%)

Which (n = 21)

Obesity (BMI > 30)

92 (53.8%)

Patient preference

74 (43.3%)

Heritable thrombophilia

60 (35.1%)

Estrogen-based hormone therapy

55 (32.2%)

No

141 (82.5%)

Gestalt (just don't feel this is the right
patient to decrease)

50 (29.2%)

Yes

30 (17.5%)

Bedbound or immobility or sedentary

36 (21.1%)

Male

16 (9.4%)

Active smoking

15 (8.8%)

ECOG Performance Status

13 (7.6%)

dose-reducing. Respondents who had been in practice greater than

Age

12 (7%)

25 years had a lower odds (OR 0.23; 95% CI 0.05–1.17; p = 0.07) of

Other

10 (5.8%)

using dose reduction compared with those in practice fewer than

6 (3.5%)

10 years. Other respondent characteristics were not found to have a

Insurance coverage
History of bleeding

145 (84.8%)

Distal DVT

132 (77.2%)

Proximal DVT

131 (76.6%)

Concurrent use of antiplatelet therapy

128 (74.9%)

Pulmonary embolism

123 (71.9%)
69 (40.4%)

Yes

4 (19%)

Dosing frequency affects decision

Abbreviations: BMI, body mass index; DOAC, direct oral coagulant;
DVT, deep vein thrombosis; VTE, venous thromboembolism.

ity analysis of dose-reduction frequency, those who did not have a
protocol had a lower odds (OR 0.23; 95% CI 0.06–0.74; p = 0.02) of
dosing frequently, meanwhile those who were unsure if a protocol
was in place had an even lower odds (OR 0.05; 95% CI 0.01–0.32;
p = 0.002) of dosing frequently (Table 4).
Upon assessing for clustering of clinicians around dose-reduction
decision-making, five clusters emerged that showed distinct patterns of behavior (Figures 1 and 2). The clusters were different as

Temporary reescalation
No

Rivaroxaban

17 (81%)

significant association with dose reduction (Table 3). In the sensitiv-

Diagnosis for reduction

Unusual site thrombosis (cerebral vein
thrombosis, splanchnic vein thrombosis)

Apixaban

106 (62%)
62 (36.3%)

Reason for temporary reescalation (n = 62)

follows: cluster 1 rarely dose reduces and is the cluster most likely
to prescribe rivaroxaban over apixaban; cluster 2 dose reduces with
considerable frequency, does not consider age when dose-reducing,
is least likely to temporarily reescalate dosing during increased VTE

Cancer (if original etiology for VTE was not
cancer)

49 (79%)

Postsurgery

47 (75.8%)

increased VTE risk; cluster 4 dose reduces with considerable fre-

Hospitalization

30 (48.4%)

quency, temporarily reescalates dosing during increased VTE risk,

Pregnancy or postpartum

30 (48.4%)

and is most likely to prescribe apixaban over rivaroxaban; and cluster

Hormone use

28 (45.2%)

5 dose reduces with highest frequency, and takes the fewest risk

Bedbound or immobility or sedentary

27 (43.5%)

factors into consideration to not dose reduce (Figure 3).

Long travel

13 (21%)

The best performing random forest model had an out-of-bag

1 (1.6%)

error rate of 67.7%. Considering that there were five clusters, an

Other

risk, and prescribes apixaban and rivaroxaban equally; cluster 3 dose
reduces <50% of the time, but temporarily reescalates dosing during

error rate <80% is better than chance. The error rates, (90.9%,

|
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TA B L E 3 Odds ratios for engaging in dose reduction; higher
odds ratio indicates more likely to dose reduce

Parameter

Odds ratio (95%
confidence interval)

5 of 9

TA B L E 4 Odds ratios for sensitivity analysis for engaging in dose
reduction; higher odds ratio indicates more likely to dose reduce
Parameter

Odds ratio (CI)

p
value

Status: attending physician

Status: attending physician
Status: nurse practitioner/physician
assistant/mid-level

0.43 (0.06–3.81)

Status: nurse practitioner/
physician assistant/mid-level

0.558
(0.149–2.120)

0.38

Status: trainee

0.44 (0.09–2.34)

Status: trainee

1.045
(0.320–3.463)

0.94

0.549
(0.270–1.100)

0.09

1.163
(0.457–3.020)

0.75

Outpatient time: 50%–79%

0.878
(0.381–2.000)

0.76

Outpatient time: ≥80%

1.043
(0.440–2.452)

0.92

Years in practice: 11–25

1.423
(0.724–2.818)

0.31

Years in practice: >25

1.334
(0.438–4.324)

0.62

Number of patients: 51–250

1.710
(0.597–4.923)

0.32

Number of patients: >250

1.675
(0.545–5.132)

0.36

International region: Europe

0.588
(0.173–1.930)

0.39

International region: other

0.411
(0.111–1.459)

0.17

US region: Midwest

0.942
(0.391–2.281)

0.89

US region: West

1.055
(0.374–3.024)

0.92

US region: Not US

0.970
(0.317–3.034)

0.96

Protocol: no

0.232
(0.063–0.740)

0.02

Protocol: don't know

0.054
(0.008–0.317)

0.002

Specialty: thrombosis
Specialty: other

0.57 (0.18–1.73)

Setting: academic
Setting: nonacademic

0.34 (0.09–1.20)

Outpatient time: <50%
Outpatient time: 50%–79%

0.89 (0.23–3.16)

Outpatient time: ≥80%

3.03 (0.71–13.20)

Years in practice: ≤10
Years in practice: 11–25

0.64 (0.21–1.91)

Years in practice: >25

0.23 (0.05–1.17)

Number of patients: <50
Number of patients: 51–250

4.03 (1.01–16.33)

Number of patients: >250

6.80 (1.36–37.75)

International region: North America
International region: Europe

0.38 (0.04–2.59)

International fegion: other

0.41 (0.04–3.05)

US region: East
US region: Midwest

1.39 (0.34–6.13)

US region: West

1.74 (0.33–11.85)

US region: not US

1.23 (0.19–11.31)

Protocol: yes
Protocol: no

0.00 (0.00–>500)

Protocol: don't know

0.00 (0.00–>500)

Specialty: thrombosis
Specialty: other
Setting: academic
Setting: nonacademic
Outpatient time: <50%

Years in practice: ≤10

Number of patients: <50

International region: North America

US region: East

95.5%, and 88.2%) were considerably high for clusters 1, 3, and 4,
respectively. The model performed well when predicting clusters
2 and 5 with error rates 36.8% and 65.7%, respectively. The respondent demographics that were most informative in determining
DOAC dosing behaviors based on the random forest analysis were
number of patients treated, geographic region, and percentage of
patients that were outpatient (Figure 4).

4
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DISCUSSION

Protocol: yes

To our knowledge, this is the first study to report patterns surrounding the decision-making process involved in dose reduction
of rivaroxaban and apixaban for extended-phase treatment of VTE.

dose reduce. Interestingly, we observed a clustering of respondents

Our study demonstrates that most clinicians surveyed elect to dose

into five groups with specific behaviors surrounding dose reduction.

reduce DOACs when prescribing extended-phase anticoagulation

We identified provider characteristics that help explain how these

therapy. Second, those who prescribe DOACs more frequently and

clusters are different from each other with a random forest model.

those who have practiced for fewer than 10 years are more likely to

We chose a random forest model for predicting clusters because

6 of 9
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F I G U R E 1 Silhouette scores for two to 10 clusters for direct oral coagulant dosing behaviors, with lower scores indicative of better
separation between the clusters

F I G U R E 2 Principal component analysis demonstrates good separation between the five clusters. A summative description of each
cluster is found in the Results.
the results (e.g., model performance, important variables) are easy

apixaban and rivaroxaban5,7 by providing important insight into how

to interpret. The random forest model was limited in its ability to

clinicians are translating these study findings into clinical practice.

associate and predict prescriber demographics within the identified

Understanding the clinician characteristics and practice behavior

clusters, which suggests that dose reduction behaviors are not read-

patterns permits greater insight into clinical practice, provides op-

ily characterized based on demographics alone.

portunities to intervene in a targeted fashion to enhance clinician

Our study builds on previously reported prospective random-

knowledge surrounding evidence for dose reduction, as well as

ized trials that demonstrate the safety and efficacy of dose-reduced

provides insight for futures studies. We assessed salient physician

GROAT et al.

|

7 of 9

F I G U R E 3 Dosing behaviors
of five clusters and entire cohort,
represented as percentage of respondents
that belong to each group. A summative
description each cluster is found in
Results paragraph 3

demographics that were characteristic of the clusters; however, the

Strengths of our work include that to our knowledge, this is the

performance of the random forest model was not consistent across

first study of its kind to explore clinician practice patterns in the

clusters, which hinders our ability to make any conclusions.

use of dose reduction of anticoagulants. Indeed, we were able to

8 of 9
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F I G U R E 4 Importance of demographic features in random forest model accuracy to predict DOAC dosing behavior clusters. DOAC,
direct oral coagulant

identify clusters of prescribing patterns in an international audience

MEE discloses Institutional funding from SPARK/Genentec/Roche,

engaged in nonmalignant hematology and anticoagulation ther-

Baxalta/Shire/Takeda, and Novo Nordisk.

apy. Limitations of our work include that most respondents self-
described as residing in an academic setting, and work from North
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America, as well as selection bias of those choosing to respond to

Danielle Groat

the survey. Additionally, cluster size was small. These limitations may
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impact the generalizability of our findings. In future work, we intend

Rachel P. Rosovsky

to solicit dose-reduction behaviors among other generalist and spe-

Kristen M. Sanfilippo

cialist physician groups.

Manila Gaddh

In conclusion, we observed that the majority of respondents to
the survey elect to dose reduce apixaban and rivaroxaban when pre-
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